Health is one of our most important personal assets and medicines play an essential role in preserving it. Yet around the world, millions lack access to comprehensive health care, including medicines and other treatment tools. Lilly is committed to expanding access to medicines, and we work with partners to improve health outcomes for underserved populations.
We recognize that poor disease outcomes—especially among low-income populations—are about more than medicine alone. Meeting patients’ needs is the result of a complex coordination of healthcare tools, healthcare professionals, supporting infrastructure, and appropriate measurement, evaluation, and regulatory capabilities.
In 2011, we launched a new platform to help address these issues, The Lilly Global Health Innovation Campaign. The campaign encompasses two of Lilly’s signature public/private programs, The Lilly NCD Partnership and The Lilly MDR-TB Partnership.
In addition to investing in these public/private partnerships, we use multiple other strategies to help increase access to medicines, including exploring differential pricing for medicines; not enforcing intellectual property rights for Lilly medicines in least-developed countries (LDCs) as defined by the United Nations; and providing donations for PAP on Lilly products through our Lilly TruAssist program and Life for a Child. In times of disaster, we donate medicines to those in need. We also support programs that improve patient outcomes, such as scholarships, award recognitions, and tools for healthy living.
Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Over time, it leads to serious damage to many of the body's systems. Since 1923, Lilly has been involved in pioneering therapies to help healthcare providers improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients.
How lilly is
tackling diabetes
across the globe
Select locations to learn how Lilly is helping
Lilly's Partner in Mexico:
Carlos Slim Health Institute
Lilly Mexico will work with (CSHI) and others to help strengthen the diabetes care capabilities at primary healthcare clinics and related healthcare system components.
Learn More
Lilly Camp Care Package
Lilly Diabetes is one of the largest providers of insulin and glucagon, educational materials, volunteers, scholarships, and special guests to diabetes camps through our comprehensive Lilly Camp Care Package program, in partnership with the American Diabetes Association and the Diabetes Education & Camping Association. Lilly Diabetes is dedicated to providing these personalized tools and resources to help children manage everyday experiences with diabetes while they're at camp—and long after.
Learn More
Lilly's Partners in South Africa: Project HOPE, The Donald Woods Foundation
Lilly and Project HOPE's new diabetes program will:
- Train community health workers at both urban and rural sites to diagnose and refer patients,
- Launch peer support groups to generate awareness and manage diabetes at the community level, and
- Strengthen clinic capabilities.
Learn More
Life for a Child
Lilly has committed to donating more than 800,000 vials of insulin to the International Diabetes Federation's Life for a Child program between 2008 and 2013. These donations, initially focused on 12 countries in sub-Saharan Africa, have now expanded to include 21 countries throughout Africa, Asia, and South America. The medicine will help as many as 24,000 children who have no access to diabetes treatment.
Learn More
Lilly's Partners in India:
Public Health Foundation of India, Project
HOPE, Population Services International
Working with our partners, we will implement a comprehensive model for diabetes care, seeking to:
- Develop diabetes awareness, patient care and provider training in one district in India,
- Improve treatment access, including oral medications and insulin, and
- Research program impact, cost-effectiveness and best practices.
Learn More
TB in all its forms is an airborne bacterial disease, which can infect any organ, although most commonly affects the lungs. Recognizing that TB and one of its deadliest forms, MDR-TB (multidrug-resistant tuberculosis), cannot be halted by medicine alone, in 2003, Lilly officially created The Lilly MDR-TB Partnership. This public/private initiative now works in four high-burden countries to tackle the scourge of TB and MDR-TB head on.
How lilly is tackling
TUBERCULOSIS
across the globe
Select locations to learn how Lilly is helping
The Lilly TB Drug Discovery Initiative
The Lilly TB Drug Discovery Initiative, launched in June 2007, is a nonprofit public/private partnership focused on accelerating early-stage TB drug discovery. Bringing together specialists from around the world for the systematic exploration of vast, private molecular libraries, the initiative has a primary goal of filling the pipeline with new clinical candidates for future TB drug development.
Learn More
Lilly’s activities in South Africa
The Lilly MDR-TB Partnership has been active in South Africa since 2004. The Partnership shares the South Africa National Department of Health’s (DOH) vision of a South Africa that is free of TB by 2050. To support this goal, the Partnership worked with the DOH to develop a holistic project strategy for 2007–2011. The project will be aligned with the National DOH’s TB Strategy—qualitative and quantitative measures on impact, such as the increase of cure rates and reduction of infectious rates for TB and MDR-TB.
Learn More
Lilly’s activities in Russia
In Russia Lilly has invested in carrying out project activities in the following areas: community support and patient advocacy, treatment, training and surveillance, awareness and prevention, and transfer of technology. The project encourages cooperation between government, private and non-governmental organizations with a view to integrate TB prevention programs into other services and ensure application of a multi-pronged approach to the treatment of TB.
Learn More
Lilly’s activities in India
The Lilly MDR-TB Partnership has been active in India since 2004 and aims to support the Government of Indias' initiatives in fighting TB and MDR-TB. The Partnership works in close coordination with the national program through training of healthcare workers, strengthening community-based interventions, and engaging in community initiatives to ensure patient adherence to a difficult treatment regimen. It also works to increase the public/private partnerships to strengthen TB control.
Learn More
Lilly’s activities in china
Lilly is working in China with local partners to promote community support and patient advocacy, implement MDR-TB treatment in areas hardest hit by TB, and work with policy makers to raise awareness to prevent the spread of MDR-TB.
Learn More
Lilly's transfer of technology
The Partnership has transferred Lilly's technology and expertise on how to manufacture two antibiotics used to treat MDR-TB. Since 2003, Lilly has transferred technology, know-how and trademarks to manufacturers in South Africa, China, India, Russia, Greece, U.S.A. and U.K. This unique approach allows patients in poorer countries to access medicines at lower prices, and also supports local economies and the manufacturing of high-quality medicines. In addition to providing manufacturing know-how and financial assistance to purchase equipment, Lilly also trained its partners on good manufacturing practices, which raised the overall standards of safety for the production of medicines.
Learn More
